期刊
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 87, 期 2, 页码 317-325出版社
WILEY
DOI: 10.1111/bcp.14723
关键词
5-fluorouracil; capecitabine; pharmacokinetics; therapeutic drug monitoring
Despite the continued importance of fluoropyrimidines in oncology, current dosing methods may not be optimal. Precision dosing approaches, such as DPD enzyme activity testing, show promise in reducing toxicity and improving patient outcomes, but have not been widely adopted in clinical practice.
Despite advances in targeted cancer therapy, the fluoropyrimidines 5-fluorouracil (5FU) and capecitabine continue to play an important role in oncology. Historically, dosing of these drugs has been based on body surface area. This approach has been demonstrated to be an imprecise way to determine the optimal dose for a patient. Evidence in the literature has demonstrated that precision dosing approaches, such as DPD enzyme activity testing and, in the case of intravenous 5FU, pharmacokinetic-guided dosing, can reduce toxicity and yield better patient outcomes. However, despite the evidence, there has not been uniform adoption of these approaches in the clinical setting. When a drug such as 5FU has been used clinically for many decades, it may be difficult to change clinical practice. With the aim of facilitating change of practice, issues and barriers to implementing precision dosing approaches for 5FU and capecitabine are identified and discussed with possible solutions proposed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据